The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SPRB | +131.9% | -95.85% | -47.07% | -93% |
| S&P | +12.66% | +85.37% | +13.13% | +97% |
Spruce Biosciences, Inc. operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
No news articles found for Spruce Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.00M | -100.5% |
| Gross Margin | 98.71% | -0.7% |
| Market Cap | $5.04M | -74.3% |
| Market Cap / Employee | $0.56M | -37.2% |
| Employees | 9 | -59.1% |
| Net Income | -$8.21M | 5.3% |
| EBITDA | -$8.23M | 12.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.67M | -82.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.50M | -62.5% |
| Short Term Debt | $0.85M | -55.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -119.08% | -74.8% |
| Return On Invested Capital | -71.53% | 673.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.32M | 42.4% |
| Operating Free Cash Flow | -$5.32M | 42.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.62 | 0.80 | 0.23 | 0.38 | 0.66% |
| Price to Sales | 3.54 | 4.38 | 2.47 | 7.23 | 161.75% |
| Price to Tangible Book Value | 25.20 | 17.40 | 14.99 | 0.38 | -98.66% |
| Enterprise Value to EBITDA | 0.77 | 0.73 | 4.23 | 0.52 | -86.85% |
| Return on Equity | -100.7% | -135.3% | -133.6% | -167.9% | 191.79% |
| Total Debt | $2.77M | $2.30M | $1.82M | $1.35M | -58.27% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
